News & Events

Oct 18 2023

Orasis Pharmaceuticals Announces FDA Approval of QLOSI™ (pilocarpine hydrochloride ophthalmic solution) 0.4% for the Treatment of Presbyopia

Feb 21 2023

FDA Accepts Orasis Pharmaceuticals’ New Drug Application for CSF-1 for the Treatment of Presbyopia 

Jan 3 2023

Orasis Pharmaceuticals Submits New Drug Application for Investigational Novel Eye Drop Candidate, CSF-1, for the Treatment of Presbyopia

Apr 23 2022

Orasis Pharmaceuticals Announces Phase 2b Trial Efficacy and Safety Results of Novel Presbyopia Eye Drop Candidate, CSF-1, at the 2022 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting

Apr 21 2022

Orasis Pharmaceuticals Announces Positive Phase 3 Topline Results of Novel Eye Drop Candidate, CSF-1, for the Treatment of Presbyopia

Apr 12 2022

Orasis Pharmaceuticals to Present New Data on Novel Presbyopia Candidate at the 2022 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting

Apr 7 2022

Orasis Pharmaceuticals Appoints Teresa (Tes) Ignacio, M.D. as Vice President, Medical Affairs

Mar 15 2022

Orasis Pharmaceuticals Concludes Phase 3 Clinical Trials  for Presbyopia Candidate

Oct 4 2021

Orasis Pharmaceuticals Appoints Julie Speed as Senior Vice President, Head of Strategy and Marketing to Lead Commercial Growth Plan

Apr 26 2021

Orasis Pharmaceuticals Appoints Industry Veteran, Paul Smith, as President and Chief Operating Officer to Lead the Next Phase of Growth

Oct 28 2020

Orasis Pharmaceuticals Announces Initiation of Phase 3 Clinical Studies of Novel Eye Drop Candidate for the Treatment of Presbyopia

Sep 10 2020

Orasis Raises $30 Million to Advance the Clinical Development of Novel Treatment for Presbyopia

Oct 10 2019

Orasis Pharmaceuticals Announces CSF-1 Eye Drop Successfully Met Primary Endpoint in Phase 2b Clinical Study in Presbyopia

Mar 27 2019

Orasis Announces Initiation of Phase 2b Clinical Study of CSF-1 for the Treatment of Presbyopia

Nov 27 2018

Orasis Announces Appointments of Richard L. Lindstrom, Eric D. Donnenfeld, and John Berdahl to its Scientific Advisory Board

Oct 22 2018

Orasis Announces the Appointment of Jeffry Weinhuff as Chairman of the Board of Directors

June 5 2018

Orasis Pharmaceuticals Closes $13 Million Series B Financing